Cloning and molecular characterization of monoclonal antibody-defined ovarian tumour antigens

Campbell, Ian; Foulkes, W. D.; Jones, T. A.; Poels, L. G.; Trowsdale, John

doi:10.1007/978-1-4757-0136-4_6

Cited by 61 publications

(79 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent studies also show that many cancers overexpress a high-affinity receptor for folic acid on their cell surfaces (28)(29)(30)(31)(32)(33). Although the conjugation of folic acid to an antisense oligonucleotide should permit its cell-specific targeting, we feel the folate-PEG-liposome formulation offers several advantages not shared by the isolated oligonucleotide.…”

Section: Discussionmentioning

confidence: 95%

Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol.

Wang

Lee

Cauchon

et al. 1995

Proc. Natl. Acad. Sci. U.S.A.

248

108

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 95%

Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol.

Wang

Lee

Cauchon

et al. 1995

Proc. Natl. Acad. Sci. U.S.A.

248

108

View full text Add to dashboard Cite

show abstract

“…[23][24][25] Folic acid, one of the most popular ligands, retains high affinity for its receptor, [45][46][47] even when linked to a variety of molecules. The folate receptor is overexpressed in various human cancers, [48][49][50][51][52] and a broad spectrum of low-and highmolecular-weight drug-folate conjugates with alkylating agents, platinum complexes, paclitaxel, 5-fluorouracil, camptothecin, doxorubicin, and mitomycin has been investigated. [53][54][55][56][57][58] Promising results for vascular receptor targeting were obtained with cyclic peptides that bind to integrins.…”

Section: Active Targetingmentioning

confidence: 99%

Prodrug Strategies in Anticancer Chemotherapy

Kratz¹,

Müller²,

Ryppa³

et al. 2008

ChemMedChem

438

425

View full text Add to dashboard Cite

The majority of clinically approved anticancer drugs are characterized by a narrow therapeutic window that results mainly from a high systemic toxicity of the drugs in combination with an evident lack of tumor selectivity. Besides the development of suitable galenic formulations such as liposomes or micelles, several promising prodrug approaches have been followed in the last decades with the aim of improving chemotherapy. In this review we elucidate the two main concepts that underlie the design of most anticancer prodrugs: drug targeting and controlled release of the drug at the tumor site. Consequently, active and passive targeting using tumor-specific ligands or macromolecular carriers are discussed as well as release strategies that are based on tumor-specific characteristics such as low pH or the expression of tumor-associated enzymes. Furthermore, other strategies such as ADEPT (antibody-directed enzyme prodrug therapy) and the design of self-eliminating structures are introduced. Chemical realization of prodrug approaches is illustrated by drug candidates that have or may have clinical importance.

show abstract

“…FR-a is highly expressed in tumor cell lines including among others, those of ovarian, kidney (MA104), colon (Caco-2), and epidermoid (KB) origin (Coney et al, 1991;Weitman et al, 1992a). FR-a is overexpressed in a variety of human neoplastic tissues, such as carcinomas of the ovary, uterus, brain, and squamous cell carcinoma of the head and neck (Campbell et al, 1991;Coney et al, 1991;Weitman et al, 1992ba, 1994Ross et al, 1994;Miotti et al, 1995;Wu et al, 1999). In contrast, FR-b expression is much more restricted.…”

Section: Folic Acid Receptor-mediated Transportmentioning

confidence: 99%